Drug Profile
PH 15
Alternative Names: PH15; PH15 NSLatest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator Pherin Pharmaceuticals
- Class Nootropics
- Mechanism of Action Chemoreceptor cell modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cognition disorders
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for phase-I development in Cognition-disorders in USA (Intranasal, Spray)
- 02 Feb 2023 Pherin Pharmaceuticals has been acquired by VistaGen Therapeutics
- 06 Jan 2022 PH 15 is still in phase I trials for Cognition disorders in USA